Hepatitis C Clinical Trial
Official title:
Epidemiology of Chronic Hepatitis C and Modelling for Disease Burden Study
Hepatitis C (HCV) is a major health problem amongst people who inject drugs (PWID) and have
limited contact with health care services. Halfway houses (HH) serve to reintegrate former
drug users into society. Strategies to eliminate HCV must focus on screening for HCV amongst
HH. Linkage to care for PWID population is an issue globally.
The aim is to determine the sero-prevalence, demographics, disease distribution and factors
associated with the risk of HCV transmission amongst former drug users at Halfway Houses. The
secondary aim would be to determine the best models of care that can be used to link these
individuals to existing healthcare services in a pragmatic, randomised fashion
Halfway Houses are invited to participate in a program of HCV education, point-of-care
screening using Oraquick test and staging with Fibroscan® by a small mobile team of
healthcare workers. A detailed survey regarding illicit drug injecting practices is
performed. Those who are tested positive are referred to medical care.
It is anticipated that the prevalence of Hepatitis C within the drug injecting population
along with the stages of liver disease such that models for disease burden can be determined.
This is a pragmatic observational study of point of care HCV screening in the halfway house
resident /PWID population.
In the secondary aim the HCV positive subjects are randomised to traditional referral pathway
(HCV positive cases attend primary care facilities to get referral to specialist clinic in
hospital) and 'direct' open access where the HCV positive cases has direct open access to
specialist clinic as above (by passing primary care physicians). We observe the no. of
subjects being linkage to specialist care, and HCV treatment
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
| Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
| Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
| Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
| Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
| Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
| Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
| Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
| Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
| Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
| Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
| Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
| Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
| Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
| Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
| Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
| Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A | |
| Completed |
NCT02869776 -
Integrating HCV and HIV Screening During the Era of HIV Antigen Testing
|
N/A |